TCL Archive Hematologic Malignancies: ASCO Meeting Highlights New Approaches To Treatment July 30, 2004
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial October 31, 2014
TCL Archive Response From Center Representatives In L.A. To NCI Questions Is “Frusterating,” DeVita Says April 13, 1984
